Is it Time to Dump Your Shares of Moderna?
Moderna stock soared early in the pandemic thanks to sales of its coronavirus vaccine.
Since then, vaccine demand has declined, and that's weighed on the stock.
Even good news from Moderna hasn't lifted the shares for long in recent times.
These 10 stocks could mint the next wave of millionaires ›
After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune. The coronavirus vaccine maker has seen revenue plummet as demand for this flagship product -- Moderna's first to be approved -- has slipped. As a result, the stock fell out of favor with investors, leading to a decline of about 80% over the past three years.
Since that time, the biotech company has delivered positive news, from the approval of a second product -- its respiratory syncytial virus (RSV) vaccine -- to the approval of updated coronavirus vaccines and progress on cost cuts. Moderna also has an impressive late-stage pipeline and goals for potential product launches on the horizon. Yet none of these elements has been enough to pull the stock out of the doldrums.
Considering this, is it time to dump your shares of Moderna? Let's find out.
First, let's back up a bit and take a look at the Moderna story, from the glory days of a few years ago to its troubles today. As mentioned, Moderna sprang to the forefront in 2021 to 2022, bringing its messenger RNA vaccine candidate to market and generating billions of dollars in revenue and profit.
Meanwhile, the biotech continued to apply this mRNA technology across its pipeline, advancing candidates for latent viruses such as cytomegalovirus (CMV), and making progress in the area of cancer vaccines. And these are just a couple of the company's late-stage programs.
But investors focused primarily on Moderna's coronavirus vaccine, which at its peak in 2022 brought in a mind-boggling $18.4 billion in annual revenue.
More recently, though, demand for coronavirus vaccination dropped, and Moderna's RSV vaccine delivered lackluster sales during its first "season" on the market -- respiratory vaccines generally see most uptake later in the year, during the cold and flu season.
Moderna has progressively cut costs and refocused resources to support its goals of bringing many vaccines to market -- across multiple treatment areas -- over the next several years. In its most recent earnings report, the biotech said it expects to reduce GAAP operating costs by between $1.4 billion and $1.7 billion by 2027.
The company continues to aim for as many as 10 product approvals within the next few years. And this includes "multiple" cancer vaccines, it says -- this is an area that Moderna has prioritized.
Its pipeline currently has seven cancer-vaccine candidates -- for a range of indications including melanoma and bladder cancer -- in phase 2 or phase 3 studies. The product-approval goal, even if only partially reached this decade, could be a game changer for Moderna, offering it multiple revenue streams -- and eventually sources of revenue at blockbuster levels.
However, as I said earlier, these positive points haven't yet led to lasting gains for the stock. Does this mean it's time to dump your Moderna shares?
First, it's important to note that Moderna's difficult times may not be over. Investors continue to focus on the decline in coronavirus vaccine sales, and to a lesser degree, the early disappointment in the RSV market. And this subject takes the spotlight as each new flu season rolls around.
On top of this, uncertainty about the Trump Administration's vaccine policies may prove to be a headwind. Most recently, Health and Human Services secretary Robert F. Kennedy Jr. let go a full panel of advisors who guide the government's vaccine decisions, saying that he would appoint new panel members.
These issues could continue to weigh on Moderna's stock performance. But even considering this, and the fact that its pipeline hasn't yet pushed it onto investors' buy lists, I still wouldn't dump shares of Moderna right now.
Why? Because the company has what it takes to succeed from a product and earnings angle, as I mentioned above. Often investors reward this ahead of time by piling into a stock as a company announces long-term prospects, but in Moderna's case, investors haven't followed that pattern.
But eventually, as Moderna approaches the product-approval finish line with key candidates, including those in the field of oncology, the revenue picture may brighten significantly. If it does, the stock could finally soar. That's why long-term investors should hold on through the tough times and get ready for Moderna's next wave of growth -- even if it takes a while for the biotech to get there.
Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this.
On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $373,325!*
Apple: if you invested $1,000 when we doubled down in 2008, you'd have $38,475!*
Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $649,102!*
Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of June 9, 2025
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy.
Is it Time to Dump Your Shares of Moderna? was originally published by The Motley Fool
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
NSSC DEADLINE TUESDAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages NAPCO Security Technologies, Inc. Investors to Secure Counsel Before Important June 24 Deadline in Securities Class Action
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NAPCO Security Technologies, Inc. (NASDAQ: NSSC) between February 5, 2024 and February 3, 2025, both dates inclusive (the 'Class Period'), of the important June 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased NAPCO securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the NAPCO class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 24, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements. Specifically, they created the false impression that they possessed reliable information pertaining to NAPCO's projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations. In truth, NAPCO's optimistic margin growth goals and demand reassurances for NAPCO's hardware sales fell short of reality; NAPCO was simply not equipped to adequately forecast demand for its products or otherwise minimized the impact of potential demand fluctuations to continue to promote its lofty margin projections which relied upon continually increased sales volumes. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the NAPCO class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Business Upturn
an hour ago
- Business Upturn
ELV FRAUD ALERT: Elevance Health, Inc. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 11 Legal Deadline (NYSE:ELV)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting Investors have until July 11, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Elevance common stock. The case is pending in the U.S. District Court for the Southern District of Indiana and is captioned Miller v. Elevance Health, Inc., et al. , No. 25-cv-0092. Why was Elevance Sued for Securities Fraud? Elevance provides health insurance plans. This includes contracting with states to administer Medicaid benefits. States routinely review Medicaid eligibility, but during COVID, the federal government paused this process. The pause ended in 2023, and states resumed redetermining Medicaid eligibility. During the relevant period, Elevance represented that it was closely monitoring the cost trends associated with the redetermination process and that the rates Elevance was negotiating were sufficient to address the risk profiles of those patients staying on Medicaid. As alleged, in truth, the redeterminations caused a significant increase in the acuity and utilization of Elevance's Medicaid members. What's more, the shift occurred to a degree that was not reflected in Elevance's rate negotiations or in its financial guidance for 2024. The Stock Declines as the Truth is Revealed On July 17, 2024, Elevance stated that it was now 'expecting second-half utilization to increase in Medicaid' and that it was 'seeing signs of increased utilization across the broader Medicaid population.' On this news, the price of Elevance stock declined $32.21 per share, or nearly 6%, from $553.14 per share on July 16, 2024, to $520.93 per share on July 17, 2024. Then, on October 17, 2024, Elevance announced its Q3 2024 financial results, revealing that its missed consensus earnings per share ('EPS') expectations by $1.33, or 13.7%, 'due to elevated medical costs in [its] Medicaid business.' On this news, the price of Elevance stock declined $52.61 per share, or nearly 11%, from $496.96 per share on October 16, 2024, to $444.35 per share on October 17, 2024. Click here if you suffered losses: What Can You Do? If you invested in Elevance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Wire
an hour ago
- Business Wire
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NeuroPace, Inc. ('NeuroPace' or 'the Company') (NASDAQ: NPCE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. NeuroPace issued a press release on May 27, 2025, "announcing the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE)." According to the Company, "The study did not reach statistical significance for the primary effectiveness endpoint in the overall study population, which was to show a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group." Based on this news, shares of NeuroPace fell by almost 28.4% on May 27, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
